Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Journal of Physiology. Endocrinology and Metabolism

• Publication date

  2006-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/AJPENDO.00101.2006PMID 16621899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle.

  2006cited by this paper
• Optimizing plasmid-based gene transfer for investigating skeletal muscle structure and function.

  2006influential reference
• Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.

  2005cited by this paper
• Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.

  2005cited by this paper
• Beta2-agonist administration increases sarcoplasmic reticulum Ca2+-ATPase activity in aged rat skeletal muscle.

  2005cited by this paper
• Insulin-like growth factor I slows the rate of denervation induced skeletal muscle atrophy.

  2005cited by this paper
• β2-Agonist administration increases sarcoplasmic reticulum Ca2+-ATPase activity in aged rat skeletal muscle

  2005cited by this paper
• Deficiency of alpha-sarcoglycan differently affects fast- and slow-twitch skeletal muscles.

  2005cited by this paper
• Transgenic Overexpression of Locally Acting Insulin-Like Growth Factor-1 Inhibits Ubiquitin-Mediated Muscle Atrophy in Chronic Left-Ventricular Dysfunction

  2005cited by this paper
• Deficiency of α-sarcoglycan differently affects fast- and slow-twitch skeletal muscles

  2005cited by this paper
• Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice.

  2005cited by this paper
• Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice.

  2004cited by this paper
• EDL and soleus muscles of the C57BL6J/dy2j laminin‐α2‐deficient dystrophic mouse are not vulnerable to eccentric contractions

  2004cited by this paper
• Administration of insulin‐like growth factor‐I improves fatigue resistance of skeletal muscles from dystrophic mdx mice

  2004influential reference
• ROLE OF CONTRACTION‐INDUCED INJURY IN THE MECHANISMS OF MUSCLE DAMAGE IN MUSCULAR DYSTROPHY

  2004cited by this paper
• β2‐Agonist administration reverses muscle wasting and improves muscle function in aged rats

  2004cited by this paper
• Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury

  2004influential reference
• The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.

  2004cited by this paper
• Susceptibility to sarcomere injury induced by single stretches of maximally activated muscles of mdx mice.

  2004cited by this paper
• Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration.

  2002influential reference
• Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin.

  2002cited by this paper
• Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice

  2002influential reference
• Muscle damage from eccentric exercise: mechanism, mechanical signs, adaptation and clinical applications

  2001cited by this paper
• Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways

  2001cited by this paper
• IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice.

  2001cited by this paper
• Contraction-induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice.

  2000cited by this paper
• The Dystrophin Complex Forms a Mechanically Strong Link between the Sarcolemma and Costameric Actin

  2000cited by this paper
• Extensive but Coordinated Reorganization of the Membrane Skeleton in Myofibers of Dystrophic (mdx) Mice

  1999cited by this paper
• Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function.

  1998cited by this paper
• Rapid recovery following contraction-induced injury to in situ skeletal muscles in mdx mice

  1998cited by this paper
• Increased oxidative capacity does not protect skeletal muscle fibers from eccentric contraction-induced injury.

  1998cited by this paper
• Increased oxidative capacity does not protect skeletal muscle fibers from eccentric contraction-induced injury.

  1998cited by this paper
• Overexpression of hIGF‐1 exclusively in skeletal muscle increases the number of dihydropyridine receptors in adult transgenic mice

  1997cited by this paper
• Contraction-induced injury to single fiber segments from fast and slow muscles of rats by single stretches.

  1996cited by this paper
• Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb

  1994influential reference
• Eccentric contraction-induced injury in normal and hindlimb-suspended mouse soleus and EDL muscles.

  1994cited by this paper
• Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch

  1993cited by this paper
• Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms.

  1993cited by this paper
• The histochemical profiles of fast fiber types IIB, IID, and IIA in skeletal muscles of mouse, rat, and rabbit.

  1993cited by this paper
• Dystrophin protects the sarcolemma from stresses developed during muscle contraction.

  1993cited by this paper
• Excitation failure in eccentric contraction‐induced injury of mouse soleus muscle.

  1993cited by this paper
• Passive force generation and titin isoforms in mammalian skeletal muscle.

  1992cited by this paper
• Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy.

  1988cited by this paper

• The Impact of Fucoidan Extracts on Heat-Stress-Induced Loss of In Vitro Fast-Twitch Muscle Function in Mice

  2025cites this paper
• Antisense oligonucleotide-mediated redirection of Igf1 alternative polyadenylation.

  2025cites this paper
• Ameliorating effects of cystine and theanine in a cancer cachexia mouse model.

  2023cites this paper
• Combined growth hormone and insulin-like growth factor-1 rescues growth retardation in glucocorticoid-treated mdxmice but does not prevent osteopenia

  2022cites this paper
• Lower insulin level is associated with sarcopenia in community-dwelling frail and non-frail older adults

  2022cites this paper
• Contraction-Induced Loss of Plasmalemmal Electrophysiological Function Is Dependent on the Dystrophin Glycoprotein Complex

  2021cites this paper
• The beneficial effect of chronic muscular exercise on muscle fragility is increased by Prox1 gene transfer in dystrophic mdx muscle

  2021cites this paper
• Oral fucoidan improves muscle size and strength in mice

  2021influential citation
• Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy

  2020cites this paper
• Recombinant human insulin‐like growth factor‐1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy

  2020cites this paper
• Prox1 gene transfer combined with voluntary exercise improves dystrophic muscle fragility in Mdx mice

  2020cites this paper
• Impaired exercise performance is independent of inflammation and cellular stress following genetic reduction or deletion of Selenoprotein S.

  2020cites this paper
• Evaluation of biological effectiveness of amino acid mixture as potential stimulator of synthetic processes in skeletal muscles

  2018cites this paper
• The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects

  2018cites this paper
• The NLRP3 inflammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice.

  2017cites this paper
• First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I.

  2017cites this paper
• Skeletal muscle-specific overexpression of IGFBP-2 promotes a slower muscle phenotype in healthy but not dystrophic mdx mice and does not affect the dystrophic pathology.

  2016cites this paper
• ROLE OF THE ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE IN MAINTAINING MUSCLE INTEGRITY AND INSULIN SENSITIVITY THROUGHOUT THE LIFESPAN

  2016cites this paper
• Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease

  2015cites this paper
• Peripheral nerve and neuromuscular junction pathology in Pompe disease.

  2015cites this paper
• Possibility of small-molecule-based pharmacotherapy for sarcopenia

  2015cites this paper
• Identification of FHL 1 as a therapeutic target for Duchenne muscular dystrophy

  2014cites this paper
• Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1.

  2014cites this paper
• Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.

  2014cites this paper
• Elevated expression of activins promotes muscle wasting and cachexia

  2014cites this paper
• Overexpression of insulin‐like growth factor‐1 attenuates skeletal muscle damage and accelerates muscle regeneration and functional recovery after disuse

  2013cites this paper
• Insulin-like growth factor-I (IGF-I) and clinical

  2013cites this paper
• Intramuscular administration of PEGylated IGF-I improves skeletal muscle regeneration after myotoxic injury.

  2013cites this paper
• Insulin-like growth factor-I (IGF-I) and clinical nutrition.

  2013cites this paper
• Molecular basis of muscle hypertrophy and atrophy: Potential therapy for muscular dystrophy

  2013cites this paper
• Hsp72 preserves muscle function and slows progression of severe muscular dystrophy

  2012cites this paper
• Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.

  2012cites this paper
• Antisense-mediated myostatin downregulation by destructive exon skipping using 2'O-methyl RNA and morpholino oligomers in skeletal muscle cells and animal models

  2012cites this paper
• The effect of exercise on IGF-I on muscle fibers and satellite cells.

  2012cites this paper
• Circulating levels of Insulin-like Growth Factor-1 are associated with muscle strength in middle-aged and oldest old women

  2012cites this paper
• Régulation du métabolisme musculaire par les facteurs de transcription SREBP-1 : rôle des MRFs, de SIRT1 et des céramides

  2012cites this paper
• Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.

  2012cites this paper
• Effects of sequential injections of hepatocyte growth factor and insulin-like growth factor-I on adult rabbit extraocular muscle.

  2012cites this paper
• Cell–matrix interactions in muscle disease

  2012cites this paper
• Separation of Fast from Slow Anabolism by Site-specific PEGylation of Insulin-like Growth Factor I (IGF-I)*

  2011cites this paper
• Emerging drugs for treating skeletal muscle injury and promoting muscle repair

  2011cites this paper
• The effect of taurine on dystrophic muscle tissue function

  2011cites this paper
• Circulating levels of IGF1 are associated with muscle strength in middle-aged- and oldest-old women.

  2011cites this paper
• Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease.

  2011cites this paper
• Regulation of mechano growth factor in skeletal muscle and heart

  2010cites this paper
• Therapeutic interventions for Duchenne Muscular Dystrophy - studies in the mdx mouse

  2010cites this paper
• Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of duchenne muscular dystrophy

  2010cites this paper
• Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology.

  2010cites this paper
• Combinatorial Gene Therapy Strategies for Treating Muscular Dystrophies

  2010cites this paper
• Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy.

  2010cites this paper
• The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis.

  2010cites this paper
• Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways

  2010cites this paper
• Antibody‐directed myostatin inhibition in 21‐mo‐old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function

  2010cites this paper
• Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia

  2009cites this paper
• Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy

  2009cites this paper
• β-hydroxy-β-methylbutyrate ( HMB ) stimulates myogenic cell proliferation , differentiation and survival via the MAPK / ERK and PI 3 K / Akt pathways

  2009cites this paper
• Beta-hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways.

  2009cites this paper
• Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures

  2009influential citation
• Fibrotic pathways in the dystrophin deficient heart

  2009cites this paper
• Genetic and cell biological analysis of integrin outside-in signaling.

  2009cites this paper
• Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts

  2009cites this paper
• mice mdx coupling in skeletal muscle fibers from dystrophic Muscle-specific overexpression of IGF-I improves E-C

  2008cites this paper
• Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

  2008cites this paper
• Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.

  2008cites this paper
• Affinity-based biosensors as promising tools for gene doping detection.

  2008cites this paper
• Insulin‐like growth factor‐I analogue protects muscles of dystrophic mdx mice from contraction‐mediated damage

  2008cites this paper
• ANABOLIC AGENTS FOR IMPROVING MUSCLE REGENERATION AND FUNCTION AFTER INJURY

  2008cites this paper
• Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle.

  2008cites this paper
• Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice.

  2008cites this paper
• Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness

  2008cites this paper
• The effects of Akt overexpression in normal and dystrophic skeletal muscle

  2007cites this paper
• Molenaar Therapeutic approaches for muscle wasting disorders

  2007cites this paper
• Individualisation de l’entraînement physique chez la souris : influence du fonds génétique sur l’adaptation musculaire, applications aux maladies du motoneurone

  2007cites this paper
• Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.

  2007cites this paper
• Therapeutic approaches for muscle wasting disorders.

  2007cites this paper
• Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia.

  2007cites this paper
• Activated calcineurin ameliorates contraction‐induced injury to skeletal muscles of mdx dystrophic mice

  2006cites this paper